Literature DB >> 8040266

Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.

J Arias-Díaz1, E Vara, C García, J L Balibrea.   

Abstract

TNF alpha seems to play an important role in the pathogenesis of adult respiratory distress syndrome. We studied the effect of TNF alpha on phospholipid synthesis by isolated type II pneumocytes and attempted to characterize the role of arachidonate metabolites and the influence of pentoxifylline on such an effect. Lung tissue obtained from both multiple organ donors (n = 14) and lung cancer patients (n = 11) was used for cell isolation. Surfactant synthesis was measured by the incorporation of D-[U-14C]glucose into phosphatidylcholine (PC). The basal PC synthesis was higher in the donor group than in the malignant group (3.44 +/- 0.19 vs 2.15 +/- 0.15 pmol/microgram protein x 120 min, P < 0.01), and, in the presence of 100 ng/ml of TNF alpha, the incorporation of labeled glucose into PC was reduced significantly in both donor (1.13 +/- 0.11 vs 3.44 +/- 0.19 pmol/microgram protein x 120 min, P < 0.01) and cancer (0.99 +/- 0.11 vs 2.15 +/- 0.15 pmol/microgram protein x 120 min, P < 0.01) groups. Indomethacin was able to completely block the cytokine-induced decrease in PC synthesis by pneumocytes from the malignant group and to attenuate the inhibitory effect of TNF alpha in those from donors, nordihydroguaiaretic acid having a similar effect. The TNF alpha effect can be blocked by pentoxifylline (100 micrograms/ml), a substance which can even succeed in reverting the basal secretory inhibition of cancer patients' pneumocytes to levels similar to those of the donor group. TNF alpha may contribute to the pathophysiology of adult respiratory distress syndrome by inhibiting the synthesis of surfactant. TNF alpha might be produced in lung tumors, resulting in chronic paracrine or systemic exposure of pneumocytes to low concentrations of the cytokine. The TNF alpha effect was not prevented completely by the blockage of the arachidonic acid metabolism, hence other mediators should also be implicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040266      PMCID: PMC296303          DOI: 10.1172/JCI117313

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Identification of rat alveolar type II epithelial cells with a tannic acid and polychrome stain.

Authors:  R J Mason; S R Walker; B A Shields; J E Henson; M C Williams
Journal:  Am Rev Respir Dis       Date:  1985-05

2.  Expression of multiple growth factors in a human lung cancer cell line.

Authors:  C Betsholtz; J Bergh; M Bywater; M Pettersson; A Johnsson; C H Heldin; R Ohlsson; T J Knott; J Scott; G I Bell
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

3.  Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin.

Authors:  L Rossignol; M Plantavid; H Chap; L Douste-Blazy
Journal:  Biochem Pharmacol       Date:  1988-09-01       Impact factor: 5.858

4.  Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor.

Authors:  M Hayakawa; N Ishida; K Takeuchi; S Shibamoto; T Hori; N Oku; F Ito; M Tsujimoto
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

5.  Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism.

Authors:  N Matthews; M L Neale; S K Jackson; J M Stark
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

6.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

7.  Modification of pulmonary responses to endotoxemia in awake sheep by steroidal and nonsteroidal anti-inflammatory agents.

Authors:  C J Begley; M L Ogletree; B O Meyrick; K L Brigham
Journal:  Am Rev Respir Dis       Date:  1984-12

8.  Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.

Authors:  M Hallman; R Spragg; J H Harrell; K M Moser; L Gluck
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

9.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Authors:  K J Tracey; H Wei; K R Manogue; Y Fong; D G Hesse; H T Nguyen; G C Kuo; B Beutler; R S Cotran; A Cerami
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  6 in total

1.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth.

Authors:  K Bry; U Lappalainen; M Hallman
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

3.  Activation of type II alveolar epithelial cells during acute endotoxemia.

Authors:  Vasanthi R Sunil; Agnieszka J Connor; Yan Guo; Jeffrey D Laskin; Debra L Laskin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-04       Impact factor: 5.464

4.  Cycloxygenase inhibition enhances the effects of surfactant therapy in endotoxin-induced rat model of ARDS.

Authors:  Neha Mittal; Sankar Nath Sanyal
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

5.  Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.

Authors:  Zaher A Radi; David K Meyerholz; Mark R Ackermann
Journal:  Viral Immunol       Date:  2010-02       Impact factor: 2.257

Review 6.  Acute respiratory distress syndrome in the septic surgical patient.

Authors:  Jose L Balibrea; Javier Arias-Díaz
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.